Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Summary

The purpose of this study is to learn about the effect of the investigational agent tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The investigators also plan to collect information on the likelihood to develop side effects while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This medication is designed to stop the tumor from developing new blood vessels.

Timeline

Start

2013-03

Primary completion

2015-02

Completion

2015-02

Outcome

Outcome not reported

Stopped: “Primary endpoint not met”

Drugs

Indications